Key result
A 79-year-old male with primary cardiac lymphoma treated with R-CHOP developed progressive heart failure requiring substitution of liposomal doxorubicin.
Case Report (n=1)
Primary cardiac lymphoma is a rare condition that requires tissue diagnosis and careful management of chemotherapy-induced cardiotoxicity.
Underscores cardiotoxicity monitoring need with R-CHOP in primary cardiac lymphoma; leaves open optimal anthracycline formulation.
Primary cardiac lymphoma (PCL) is a rare disease entity that can present with severe cardiac and cardioembolic symptoms. We present a 79-year-old male with history of polymalgia rheumatica on chronic prednisone who presented with a two-week history of progressively worsening dyspnea, cough, and a 10 pound weight loss. Transthoracic echocardiogram (TTE) and computed tomography (CT) of the chest showed a large mediastinal mass with invasion of the pericardium. A biopsy of an abdominal soft-tissue mass confirmed the diagnosis of PCL. The patient was treated with two cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) which was complicated by progressive heart failure requiring substitution of liposomal doxorubicin. The epidemiology, presentation, diagnosis, and treatment options of PCL are discussed.
No takes yet. Share an insight, caveat, or question.
Mendelson et al. (2018) conducted a case report in Primary cardiac lymphoma (n=1). R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) was evaluated. A 79-year-old male with primary cardiac lymphoma treated with R-CHOP developed progressive heart failure requiring substitution of liposomal doxorubicin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: